Recent insider trends for Argos Therapeutics, Inc. (NASDAQ:ARGS) have caught the attention of investors. Insider activity is often a strong indicator of future performance in a stock, and if the data on ARGS is anything to go by, investors should pay attention.
Institutions own 28.06% of Argos Therapeutics, Inc. (ARGS)’s shares. The total value of these holdings, in millions, is $3. Among active positions in the latest quarter, 17 holders increased their positions by a total of 644311 shares, 31 holders decreased the positions by a total of 2.13 million shares, and 4 holders held their positions. This works out to a net decrease in ownership of 1.48 million shares, and suggests that institutions are feeling bearish about the stock.
Among new and sold out positions, 8 holders initiated new positions by a total of 510690 shares and 14 holders exited their positions by a total of 684869 shares. This nets out to a decrease of 174179 shares and is another bearish sign for ARGS.
In the last three months, insiders executed a total of 4 trades. 4 of these were buys and 0 were sells. Insider ownership increased by a total of 1.84 million shares, which suggests that ARGS’s key executives are feeling more optimistic about the outlook for the stock. The data from the past twelve months tells a similar story: insiders executed 33 buys and 0 sells, and ownership increased by a net of 2.13 million shares.
Analysts often look at short interest, or the number of shares currently being shorted by investors, to aid in their outlook for a particular stock. Argos Therapeutics, Inc. (NASDAQ:ARGS)’s short interest is 3.04 million shares, or 14.13% of the float. This represents a decrease of -4% in the number of shares being shorted compared to the previous reading, and implies that investors felt less pessimistic about the stock during the past two weeks.
Supplementing insider data with technical indicators can help an investor form a more complete view on the outlook for a stock. A composite of 13 technical indicators that includes measures such as moving averages and momentum oscillators suggests that ARGS is a Strong sell, which implies that ARGS is expected to underperform the market based on prior trading patterns.
Institutional ownership trends suggest that the stock is cheap and the insider trading data indicates that insiders are bullish. Technical indicators (also) suggest that Argos Therapeutics, Inc. (NASDAQ:ARGS) is overvalued.